Fennec rises as medical body recommends co's hearing loss therapy

Fennec Pharmaceuticals

25/01/2023 14:25

** Shares of Fennec Pharmaceuticals Inc  FENC.O  gain 10% to
$10.11 premarket
    ** Co announced that the updated clinical practice
guidelines for Adolescent and Young Adult Oncology from the
National Comprehensive Cancer Network (NCCN) includes co's
injection Pedmark
    ** Pedmark is a sodium thiosulfate-based injection to help
reduce chemotherapy-induced hearing loss in children
    ** NCCN is a not-for-profit alliance of 32 leading cancer
centers, which frame guidelines detailing recommendations for 
prevention, diagnosis, and management of cancer
    ** Fennec stock has doubled in last 12 months
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))